Brief: Foghorn Therapeutics Provides Update On Phase 1 Study Of Fhd-286 In Relapsed And/Or Refractory Aml And Mds

Foghorn Therapeutics

19/05/2022 22:17

May 19 (Reuters) - Foghorn Therapeutics Inc.  FHTX.O :
    * FOGHORN THERAPEUTICS PROVIDES UPDATE ON PHASE 1 STUDY OF
FHD-286
IN RELAPSED AND/OR REFRACTORY AML AND MDS
    * FOGHORN THERAPEUTICS INC. - FDA HAS PLACED PHASE 1 DOSE
ESCALATION STUDY OF FHD-286 IN RELAPSED AND/OR REFRACTORY AML
AND MDS ON PARTIAL CLINICAL HOLD
    * FOGHORN THERAPEUTICS INC. - PARTIAL HOLD WAS INITIATED BY
FDA
AFTER REPORT OF RECENT DEATH IN SUBJECT WITH POTENTIAL
DIFFERENTIATION SYNDROME
    * FOGHORN THERAPEUTICS INC. - FDA REQUESTED REVIEW OF SAFETY
DATABASE, RISK MITIGATION STRATEGIES, BREAKDOWN OF CLINICAL
ACTIVITY ACROSS DOSE LEVELS
    * FOGHORN THERAPEUTICS -  UNTIL CO HAS RESOLVED PARTIAL
CLINICAL
HOLD, SUSPENDING GUIDANCE ON TIMING OF DATA RELEASE FOR FHD-286
PROGRAM

Source text for Eikon:  ID:nGNX3tL9XW 
Further company coverage:  FHTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))